Molecular Oncology
Volume 4, Issue 5 , Pages 451-457 , October 2010

Progress in understanding melanoma propagation

  • Mark Shackleton

      Affiliations

    • Melanoma Research Laboratory and Department of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne 3002, Australia
    • Department of Pathology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville 3010, Australia
    • Howard Hughes Medical Institute, Life Sciences Institute, Department of Internal Medicine and Center for Stem Cell Biology, University of Michigan, Ann Arbor, MI 48109-2216, USA
    • Corresponding Author InformationCorresponding author. Melanoma Research Laboratory and Department of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne 3002, Australia. Tel.: +61 3 9656 5235; fax: +61 3 9656 1411.
    • ,
  • Elsa Quintana

      Affiliations

    • Howard Hughes Medical Institute, Life Sciences Institute, Department of Internal Medicine and Center for Stem Cell Biology, University of Michigan, Ann Arbor, MI 48109-2216, USA
    • Present address: Departamento de Farmacología, Facultad de Medicina, Universidad de Valencia, Avd. Blasco Ibáñez, Valencia, Spain.

Received 12 May 2010 ,Revised 15 June 2010 ,Accepted 16 June 2010.

References 

  1. Bennett DC. Differentiation in mouse melanoma cells: initial reversibility and an on–off stochastic model. Cell. 1983;34:445–453
  2. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature. 2010;466:133–137
  3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954
  4. Dick JE. Stem cell concepts renew cancer research. Blood. 2008;112:4793–4807
  5. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008;451:1111–1115
  6. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl. Acad. Sci. U S A. 2009;106:20411–20416
  7. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005;65:9328–9337
  8. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–767
  9. Flaherty K, Puzanov I, Sosman J, Kim K, Ribas A, McArthur G, et al. Phase 1 study of PLX4032: Proof of concept for V600E BRAF mutationas a therapeutic target in human cancer. J. Clin. Oncol. 2009;27:suppl; abstr 9000
  10. Foulds L. The natural history of cancer. J. Chronic Dis. 1958;8:2–37
  11. Gedye C, Quirk J, Browning J, Svobodova S, John T, Sluka P, et al. Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. Cancer Immunol. Immunother. 2009;58:1635–1646
  12. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality?. Nat. Med. 2009;15:1010–1012
  13. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140:209–221
  14. Held MA, Curley DP, Dankort D, McMahon M, Muthusamy V, Bosenberg MW. Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Res. 2010;70:388–397
  15. Hoek KS, Eichhoff OM, Schlegel NC, Dobbeling U, Kobert N, Schaerer L, et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 2008;68:650–656
  16. Hu S, Parmet Y, Allen G, Parker DF, Ma F, Rouhani P, et al. Disparity in melanoma: a trend analysis of melanoma incidence and stage at diagnosis among whites, Hispanics, and blacks in Florida. Arch. Dermatol. 2009;145:1369–1374
  17. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods. 2009;347:70–78
  18. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science. 2007;317:337
  19. Kim M, Gans JD, Nogueira C, Wang A, Paik JH, Feng B, et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell. 2006;125:1269–1281
  20. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396:643–649
  21. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu. Rev. Cell Dev. Biol. 2007;23:675–699
  22. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–715
  23. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim. Biophys. Acta. 2010;1805:105–117
  24. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur. J. Cancer. 2007;43:935–946
  25. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194:23–28
  26. O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106–110
  27. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J. Cutan. Pathol. 2008;35:433–444
  28. Pinner S, Jordan P, Sharrock K, Bazley L, Collinson L, Marais R, et al. Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Cancer Res. 2009;69:7969–7977
  29. Prasmickaite L, Skrbo N, Hoifodt HK, Suo Z, Engebraten O, Gullestad HP, et al. Human malignant melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cells. Pigment Cell Melanoma Res. 2010;
  30. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature. 2008;456:593–598
  31. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–111
  32. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111–115
  33. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 2010;141:583–594
  34. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008;451:1116–1120
  35. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, et al. Identification of cells initiating human melanomas. Nature. 2008;451:345–349
  36. Shackleton M. Normal stem cells and cancer stem cells: similar and different. Semin Cancer Biol. 2010;20:85–92
  37. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009;138:822–829
  38. Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Invest. 2007;117:2562–2569
  39. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141:69–80
  40. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 2005;174:6477–6489
  41. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401
  42. Stemple DL, Anderson DJ. Isolation of a stem cell for neurons and glia from the mammalian neural crest. Cell. 1992;71:973–985
  43. Takata M, Morita R, Takehara K. Clonal heterogeneity in sporadic melanomas as revealed by loss-of-heterozygosity analysis. Int. J. Cancer. 2000;85:492–497
  44. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N. Engl. J. Med. 2004;351:998–1012
  45. Wallace ME, Smyth MJ. The role of natural killer cells in tumor control–effectors and regulators of adaptive immunity. Springer Semin. Immunopathol. 2005;27:49–64
  46. Weatherhead SC, Haniffa M, Lawrence CM. Melanomas arising from naevi and de novo melanomas–does origin matter?. Br. J. Dermatol. 2007;156:72–76
  47. Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008;68:3077–3080discussion 3080
  48. Williams RT, den Besten W, Sherr CJ. Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. Genes Dev. 2007;21:2283–2287
  49. Yang YG, Sykes M. Xenotransplantation: current status and a perspective on the future. Nat. Rev. Immunol. 2007;7:519–531
  50. Zhong Y, Guan K, Zhou C, Ma W, Wang D, Zhang Y, et al. Cancer stem cells sustaining the growth of mouse melanoma are not rare. Cancer Lett. 2010;292:17–23

PII: S1574-7891(10)00054-2

doi: 10.1016/j.molonc.2010.06.006

Molecular Oncology
Volume 4, Issue 5 , Pages 451-457 , October 2010

Article Tools

* Image Usage & Resolution